此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

2021年2月5日 更新者:Zhenyu Zhang、The First Affiliated Hospital of Zhengzhou University

MR and Histopathology Images Based Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas Using Artificial Intelligence

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.

研究概览

地位

招聘中

干预/治疗

详细说明

Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib.

研究类型

观察性的

注册 (预期的)

600

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Henan
      • Zhengzhou、Henan、中国、450052
        • 招聘中
        • Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 90年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Subjects are all received anti-angiogenesis drug (Apatinib) in the First Affiliated Hospital of Zhengzhou University.

描述

Inclusion Criteria:

  1. Adult patients with histologically-confirmed WHO Grade II-IV gliomas which have recurrent or progressive conditions.
  2. With measurable or evaluable disease defined by RANO criteria by MRI scan.
  3. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
  4. Life expectancy ≥3 months.
  5. No evidence of serious cardiopulmonary function damage, postoperative complication and hemorrhage on the baseline.
  6. No history of serious hypertension disease.
  7. Patients have adequate organ function as defined by the following criteria:

    • Hemoglobin (HGB) ≥90g/L
    • Absolute neutrophil count (ANC) ≥1.5×109/L
    • White blood cell (WBC) ≥3.0×109/L
    • Platelet count ≥80×109/L
    • Alanine aminotransferase(ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis
    • Creatinine (Cr) of ≤1.25 UNL or creatinine clearance(Ccr) > 45 ml/min.
  8. With written informed consent signed voluntarily by patients themselves.

Exclusion Criteria:

  1. Patients with age<18 or >90 years.
  2. Pregnant or lactating women.
  3. Inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 mmHg on antihypertensive medications).
  4. New York Heart Association (NYHA) Grade II or greater congestive heart failure.
  5. Factors that could have an effect on oral medication.
  6. Abnormal Coagulation (international normalized ratio>1.5, prothrombin time>UNL+4s,activated partial thromboplastin time>1.5 UNL), with tendency of bleeding.
  7. Currently receive thrombolytic and anticoagulation therapy
  8. History of pneumorrhagia(CTCAE grade ≥2 ) or other parts hemorrhage(CTCAE grade ≥3 ) within 4 weeks prior to treatment.
  9. History of artery thrombosis and phlebothrombosis, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, within 6 month prior to treatment.
  10. Medical history of clinically significant thrombosis (bleeding or clotting disorder), excluding warfarin(1mg po qd) and aspirin(80-100mg po qd) for prevention under INR≤1.5.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Apatinib
Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Changes of Response to Treatment
大体时间:From enrollment to progression of disease. Estimated about 6 months
Response were evaluated with Response Assessment in Neuro-Oncology (RANO) criteria every 1 month after treament.
From enrollment to progression of disease. Estimated about 6 months

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:From enrollment to progression of disease. Estimated about 6 months.
The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)
From enrollment to progression of disease. Estimated about 6 months.
Overall Survival (OS)
大体时间:From enrollment to death of patients. Estimated about 1 year.
The length of time from enrollment until the time of death (OS, overall survival)
From enrollment to death of patients. Estimated about 1 year.
Incidence of treatment-related adverse events
大体时间:Time Frame: 0 to 1 year
The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Time Frame: 0 to 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年1月1日

初级完成 (预期的)

2025年1月1日

研究完成 (预期的)

2025年6月1日

研究注册日期

首次提交

2019年12月31日

首先提交符合 QC 标准的

2019年12月31日

首次发布 (实际的)

2020年1月2日

研究记录更新

最后更新发布 (实际的)

2021年2月8日

上次提交的符合 QC 标准的更新

2021年2月5日

最后验证

2021年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

Undecided

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅